SUPPLEMENT ARTICLE

Recommendations for the Pharmacological Management  
of Neuropathic Pain: An Overview and Literature Update 

Robert H. Dworkin, PhD; Alec B. O’Connor, MD; Joseph Audette, MD; Ralf Baron, Dr Med;  

Geoffrey K. Gourlay, PhD; Maija L. Haanpää, MD, PhD; Joel L. Kent, MD; Elliot J. Krane, MD;  
Alyssa A. LeBel, MD; Robert M. Levy, MD, PhD; Sean C. Mackey, MD, PhD; John Mayer, DC, PhD; 

Christine Miaskowski, RN, PhD; Srinivasa N. Raja, MD; Andrew S. C. Rice, MB, MD, FRCA;  

Kenneth E. Schmader, MD; Brett Stacey, MD; Steven Stanos, DO; Rolf-Detlef Treede, Dr Med; 

Dennis C. Turk, PhD; Gary A. Walco, PhD; and Christopher D. Wells, MB

The Neuropathic Pain Special Interest Group of the International 
Association for the Study of Pain recently sponsored the develop-
ment of evidence-based guidelines for the pharmacological treat-
ment of neuropathic pain. Tricyclic antidepressants, dual reuptake 
inhibitors of serotonin and norepinephrine, calcium channel α2-δ  
ligands  (ie,  gabapentin  and  pregabalin),  and  topical  lidocaine 
were  recommended  as  ﬁrst-line  treatment  options  on  the  basis 
of the results of randomized clinical trials. Opioid analgesics and 
tramadol were recommended as second-line treatments that can 
be considered for ﬁrst-line use in certain clinical circumstances. 
Results  of  several  recent  clinical  trials  have  become  available 
since  the  development  of  these  guidelines.  These  studies  have 
examined  botulinum  toxin,  high-concentration  capsaicin  patch, 
lacosamide,  selective  serotonin  reuptake  inhibitors,  and  com-
bination  therapies  in  various  neuropathic  pain  conditions.  The 
increasing  number  of  negative  clinical  trials  of  pharmacological 
treatments for neuropathic pain and ambiguities in the interpreta-
tion of these negative trials must also be considered in developing 
treatment guidelines. The objectives of the current article are to 
review  the  Neuropathic  Pain  Special  Interest  Group  guidelines 
for the pharmacological management of neuropathic pain and to 
provide a brief overview of these recent studies.

Mayo Clin Proc. 2010;85(3)(suppl):S3-S14

DPN = diabetic peripheral neuropathy; HIV = human immunodeﬁciency 
virus;  HRQoL  =  health-related  quality  of  life;  NeuPSIG  =  Neuropathic 
Pain Special Interest Group; NP = neuropathic pain; PHN = postherpetic 
neuralgia; RCT = randomized clinical trial; SSNRI = selective serotonin 
norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; TCA = tricyclic antidepressant

Neuropathic pain (NP) has recently been redefined as 

“pain  arising  as  a  direct  consequence  of  a  lesion  or 
disease affecting the somatosensory system.”1 Several re-
cent studies have shown that NP can adversely affect pa-
tients’ overall health-related quality of life (HRQoL), in-
cluding physical and emotional functioning,2-6 and that it is 
associated with substantial societal costs.6-11
  Neuropathic pain is challenging to manage, and many 
patients have pain that is refractory to existing treatments. 
In  randomized  clinical  trials  (RCTs)  that  have  examined 
pharmacotherapy, no more than half of patients experience 
clinically meaningful pain relief, which is almost always 
partial  but  not  complete  relief.  In  addition,  patients  fre-
quently  experience  burdensome  adverse  effects  and  as  a 

consequence are often unable to tolerate the treatment. Re-
sults of RCTs are consistent with several studies of NP in 
the community, which have also shown that patients con-
tinue to have, on average, pain of moderate severity despite 
taking prescribed medications for their pain.6
  Because  of  limitations  in  the  current  treatment  of  pa-
tients with NP, the Neuropathic Pain Special Interest Group 
(NeuPSIG) of the International Association for the Study 
of  Pain  sponsored  the  development  of  evidence-based 
guidelines  for  the  pharmacological  treatment  of  NP  that 
take into account clinical efficacy, adverse effects, effects 

From  the  Department  of  Anesthesiology  (R.H.D.,  J.L.K.),  Department  of 
Neurology (R.H.D.), and Department of Medicine (A.B.O.), University of Roch-
ester School of Medicine and Dentistry, Rochester, NY; Department of Pain 
Medicine, Harvard Vanguard Medical Associates, Boston, MA (J.A.); Division 
of Neurological Pain Research and Therapy, Universitatsklinikum Schleswig-
Holstein, Kiel, Germany (R.B.); Pain Management Unit, Flinders Medical Cen-
tre, Bedford Park, South Australia, Australia (G.K.G.); Rehabilitation ORTON, 
Helsinki, Finland, and Department of Neurosurgery, Helsinki University Central 
Hospital, Helsinki, Finland (M.L.H.); Pain Management Division, Stanford Uni-
versity School of Medicine, Stanford, CA (E.J.K., S.C.M.); Pain Management 
Service, Lucile Packard Children’s Hospital, Stanford, CA (E.J.K.); Division of 
Pain  Medicine,  Department  of  Anesthesiology,  Children’s  Hospital  Boston, 
Boston,  MA  (A.A.L.);  Department  of  Neurological  Surgery,  Northwestern 
University,  Chicago,  IL  (R.M.L.);  School  of  Physical  Therapy  and  Rehabilita-
tion Sciences, University of South Florida College of Medicine, Tampa (J.M.); 
Department of Physiological Nursing, University of California, San Francisco 
(C.M.); Department of Anesthesiology and Critical Care Medicine, Johns Hop-
kins School of Medicine, Baltimore, MD (S.N.R.); Department of Anaesthetics, 
Pain Medicine and Intensive Care, Imperial College, London, United Kingdom 
(A.S.C.R.); Department of Medicine-Geriatrics, Center for the Study of Aging, 
Duke University Medical Center, and Geriatrics Research Education and Clini-
cal Center, Durham VA Medical Center, Durham, NC (K.E.S.); Department of 
Anesthesiology, Oregon Health and Science University, Portland (B.S.); Center 
for Pain Management, Rehabilitation Institute of Chicago, Chicago, IL (S.S.); 
Universität Heidelberg, Medizinische Fakultät Mannheim, Germany (R.-D.T.); 
Department of Anesthesiology & Pain Medicine, Seattle Children’s Hospital, 
Seattle,  WA  (D.C.T.,  G.A.W.);  and  Pain  Matters  Ltd,  Pain  Relief  Foundation, 
Liverpool, United Kingdom (C.D.W.).

Support for the meeting on which this article is based and article preparation 
was provided by an unrestricted grant from Endo Pharmaceuticals to the Uni-
versity of Rochester Office of Continuing Professional Education, from which 
all authors received honoraria for their participation. Individual disclosures 
can be found on page S11.

Address correspondence to Robert H. Dworkin, PhD, Department of Anesthe-
siology, University of Rochester School of Medicine and Dentistry, Box 604, 
601  Elmwood  Ave,  Rochester,  NY  14642  (robert_dworkin@urmc.rochester 
.edu).

© 2010 Mayo Foundation for Medical Education and Research

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S3

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

on HRQoL, convenience, and costs.12 The objectives of the 
current article are to review these guidelines and to discuss 
results of recent studies that should be considered in the de-
velopment of future pharmacological recommendations for 
NP. Although consensus guidelines for the pharmacologi-
cal treatment of NP were also developed simultaneously by 
the  European  Federation  of  Neurological  Societies13  and 
the Canadian Pain Society,14 it is beyond the scope of the 
current article to discuss these guidelines (a comparison of 
all 3 guidelines has been published15).
  Several general considerations and limitations should 
be emphasized regarding pharmacological treatment rec-
ommendations  for  NP.  First,  despite  the  fact  that  many 
types of peripheral and central NP occur in clinical prac-
tice, most RCTs have examined patients with either pos-
therpetic neuralgia (PHN) or painful diabetic peripheral 
neuropathy  (DPN).  Second,  there  are  few  head-to-head 
trials comparing different treatments and so direct com-
parisons of efficacy and tolerability are generally not pos-
sible.  Indirect  comparisons  of  different  treatments  are 
problematic because RCTs differ substantially in research 
design and outcomes reported. Many older RCTs used a 
crossover design, whereas newer medications have typi-
cally been studied using a parallel group research design. 
Outcome measures have also differed over time and across 
studies,  with  more  recent  RCTs  assessing  treatment  re-
sponse more comprehensively and including measures of 
HRQoL and patient global assessments of improvement 
and satisfaction, which were not collected in many older 
trials. Finally, treatment duration in RCTs of medications 
for  NP  has  been  relatively  short,  typically  3  months  or 
less, which is in marked contrast to the chronic nature of 
most NP conditions and makes it impossible to extrapolate 
the results to long-term use.
  The limitations of existing research constitute substan-
tial challenges in developing treatment recommendations 
for NP. For example, the extent to which efficacy estab-
lished in relatively short-term trials of PHN and painful 
DPN can be extrapolated to other conditions and to long-
term use is unknown. In addition, appreciation of the con-
siderable heterogeneity among different NP conditions is 
increasing, not only in responsiveness to different treat-
ments but also in other factors, such as their patterns of 
signs  and  symptoms  (ie,  their  “sensory  phenotype”).16,17 
Moreover,  the  lack  of  direct  comparisons  of  different 
medications makes it difficult to contrast and rank medi-
cations  on  the  basis  of  efficacy,  safety,  and  tolerability. 
Therefore, the choice of medication in an individual pa-
tient with NP depends on a number of factors, including 
the potential for adverse effects, treatment of comorbidi-
ties  (eg,  depression,  sleep  disorders),  drug  interactions, 
risks of misuse and abuse, and cost.

GUIDELINES FOR THE PHARMACOLOGICAL  

MANAGEMENT OF NP 

The NeuPSIG guidelines recommend medications as first-
line  treatment  if  efficacy  in  NP  has  been  established  in 
multiple RCTs (Oxford Centre for Evidence-based Medi-
cine grade A recommendation18), and these results are con-
sistent with the authors’ clinical experience; as second-line 
if  efficacy  in  NP  has  been  established  in  multiple  RCTs 
(grade  A  recommendation),  but  there  were  reservations 
about  the  use  of  the  medication  relative  to  the  first-line 
medications based on the authors’ clinical experience; and 
as third-line if only one RCT has shown efficacy in NP or 
if the results of 2 or more RCTs were inconsistent (grade B 
recommendation), but the authors thought that in selected 
circumstances  the  medication  may  be  a  reasonable  treat-
ment option.12 These consensus guidelines were not intend-
ed to apply to pediatric patients, patients with trigeminal 
neuralgia (for which separate treatment recommendations 
are available13,14,19,20), or conditions that are not clearly NP 
(eg, fibromyalgia and irritable bowel syndrome). They also 
do  not  take  into  account  prescribing  challenges  faced  in 
some developing and currency-restricted countries.
  Because many patients treated with a single efficacious  
medication do not obtain satisfactory pain relief, the guide-
lines emphasize that patients may benefit from use of com-
binations of efficacious NP medications. A stepwise man-
agement strategy for patients with NP is presented in Table 
1, and specific guidelines for use of the first- and second-
line  medications  discussed  in  this  article  are  provided  in 
Table 2.

FIRST-LINE MEDICATIONS 
  Antidepressants  With  Both  Norepinephrine  and  
Serotonin Reuptake Inhibition. A large number of pla-
cebo-controlled RCTs have found tricyclic antidepressants 
(TCAs) to be efficacious for several different types of NP 
(see later section regarding negative trials in painful human 
immunodeficiency virus [HIV] and chemotherapy-associ-
ated peripheral neuropathy).21 In addition, TCAs are effica-
cious for the treatment of depression, a common comorbid-
ity in patients with chronic pain, but their analgesic efficacy 
in NP has been established in nondepressed patients,22 which 
demonstrates  that  their  beneficial  effects  in  NP  cannot  be 
explained  simply  by  their  antidepressant  effects. They  are 
inexpensive and have the convenience of being administered 
once  daily.  However,  anticholinergic  adverse  effects  are 
common  and  include  dry  mouth,  orthostatic  hypotension, 
constipation, and urinary retention. These effects can be re-
duced by starting with low dosages administered at bedtime 
and with slow titration to higher dosages and also by using 
a secondary amine TCA (nortriptyline or desipramine).12,21 

S4

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

TABLE 1. Stepwise Pharmacological Management of Neuropathic Pain

Establish and treat the cause of NP; if uncertain about availability of treatments for cause of NP, refer to appropriate specialist
Identify relevant comorbidities (eg, cardiac, renal, or hepatic disease, depression, gait instability) that might be relieved or exacerbated by NP   
  treatment or that might require dosage adjustment or additional monitoring of therapy
Explain the diagnosis and treatment plan to the patient and establish realistic expectations

Initiate therapy for the disease causing NP, if applicable
Initiate symptom treatment with one or more of the following:
 
 
 
 
 
 
Evaluate patient for nonpharmacological treatments and initiate if appropriate

Step 1
  Assess pain and establish the diagnosis of NP; if uncertain about the diagnosis, refer to a pain specialist or neurologist
 
 
 
 
Step 2
 
 
 
 
 
 
 
 
 
Step 3
  Reassess pain and health-related quality of life frequently
 
 
 
Step 4
 
 

If substantial pain relief (eg, average pain reduced to ≤3/10) and tolerable adverse effects, continue treatment
If partial pain relief (eg, average pain remains ≥4/10) after an adequate trial, add one of the other 4 first-line medications
If no or inadequate pain relief (eg, <30% reduction) at target dosage after an adequate trial, switch to an alternative first-line medication

  A secondary-amine TCA (nortriptyline, desipramine) or an SSNRI (duloxetine, venlafaxine)
  A calcium channel α2-δ ligand, either gabapentin or pregabalin
  For patients with localized peripheral NP, topical lidocaine used alone or in combination with one of the other first-line therapies
  For patients with acute NP, neuropathic cancer pain, or episodic exacerbations of severe pain and when prompt pain relief during titration of a  
 
 

  first-line medication to an efficacious dosage is required, opioid analgesics or tramadol may be used alone or in combination with 1 of the  
  first-line therapies

If trials of first-line medications alone and in combination fail, consider second- and third-line medications or referral to a pain specialist or  
  multidisciplinary pain center

NP = neuropathic pain; SSNRI = selective serotonin norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant.
From Pain,12 with permission of the International Association for the Study of Pain® (IASP®). This table cannot be reproduced for any other purpose 
without permission.

Cardiac toxicity is a concern, and the NeuPSIG guidelines 
recommend prescribing TCAs with caution in patients with 
ischemic  cardiac  disease  or  ventricular  conduction  abnor-
malities, limiting the dosages to less than 100 mg/d when 
possible,  and  obtaining  a  screening  electrocardiogram  for 
patients older than 40 years. It can take 6 to 8 weeks, includ-
ing 2 weeks at the highest dosage tolerated, for an adequate 
trial of treatment with a TCA (Table 2).
  Duloxetine and venlafaxine are selective serotonin nor-
epinephrine  reuptake  inhibitors  (SSNRIs)  that  have  been 
studied in peripheral NP (a third SSNRI, milnacipran, has 
been studied only in fibromyalgia). Duloxetine has shown 
consistent  efficacy  in  painful  DPN,12  with  effectiveness 
sustained for 1 year in an open-label trial.23 Unfortunately, 
duloxetine has not been studied in other types of NP, and 
so its efficacy in such conditions is unknown. Duloxetine 
has  shown  efficacy  in  the  treatment  of  major  depression 
and generalized anxiety disorder, and its dosing is simple, 
with 60 mg once daily appearing to be as effective as 60 
mg twice daily. The most common adverse effect of dulox-
etine is nausea, which seems to be reduced by administer-
ing 30 mg once daily for 1 week before increasing to 60 mg 
once daily (Table 2). Duloxetine does not seem to produce 
clinically important electrocardiographic or blood pressure 
changes,24 and a recent review concluded that aminotrans-
ferase monitoring is unnecessary.25

  Venlafaxine  has  shown  efficacy  in  painful  DPN  and 
painful  polyneuropathies  of  different  origins  but  not  in 
PHN.12  Typically,  2  to  4  weeks  are  required  to  titrate  to 
an efficacious dosage (ie, 150-225 mg/d); venlafaxine is 
available in short- and long-acting preparations (Table 2). 
Cardiac conduction abnormalities have been reported in a 
small number of patients,26 and blood pressure increases 
can  occur;  therefore,  venlafaxine  should  be  prescribed 
with caution in patients with cardiac disease. In addition, 
venlafaxine  should  be  tapered  when  treatment  is  being 
discontinued  because  a  withdrawal  syndrome  has  been 
described.27
  Calcium  Channel  α2-δ  Ligands  (Gabapentin  and 
Pregabalin).  Gabapentin  and  pregabalin  each  bind  to 
voltage-gated calcium channels at the α2-δ subunit and in-
hibit neurotransmitter release. They have shown efficacy vs 
placebo in several NP conditions.12,21 Although gabapentin 
and pregabalin have few drug interactions, both can pro-
duce dose-dependent dizziness and sedation, which can be 
reduced by starting with lower dosages and titrating cau-
tiously. Both medications also require dosage reduction in 
patients  with  renal  insufficiency,  and  dosage  adjustments 
can be made in relation to creatinine clearance.
  Gabapentin  pharmacokinetics  are  nonlinear  (due  to 
saturable absorption), and dosing requires careful titration. 
Treatment should be initiated at low dosages with gradual 

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S5

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

TABLE 2. Prescribing Recommendations for First-line Medications and Opioid Agonistsa

 
 

 

 

Starting dosage 

Titration 

Maximum dosage 

 

 

 

 

 

4 wk

4-6 wk

Duration of
adequate trial 

60 mg twice daily 
 
225 mg/d 

6-8 wk with at 
  least 2 wk at 
  maximum 
  tolerated dosage

   
25 mg at bedtime 
 
 
 

 
 
 

Increase to 60 mg  
  once daily after 1 wk 
Increase by 75 mg each 
  week 

30 mg once daily 
 
 
37.5 mg once or twice  
  daily 

  desipramineb (use  
  tertiary amine TCA 
  only if secondary amine 
  TCA not available)

 
Increase by 25 mg/d  
  every 3-7 d as tolerated 
 
 

 
 

 
 
 

 
 
 

  Gabapentinb 
 
 
 
  Pregabalinb 
 
 
 

 
 
 

 
 
 

150 mg/d; if blood concentration 
  of active medication and its 
  metabolite is <100 ng/mL (mg/L),  
  continue tritation with caution 

100-300 mg at bedtime 
  or 100-300 mg 
  3 times daily 
 
50 mg 3 times daily or  
  or 75 mg twice daily 
  as tolerated 
 
 

 
 
 
Medication class 
Secondary-amine TCAs 
  Nortriptylineb or  
 
 
 
 
 
 
 
 
 
SSNRIs
  Duloxetine 
 
 
 
 
  Venlafaxine 
 
 
 
 
Calcium channel α2-δ ligands
 
 
 
 
 
 
 
 
Topical lidocaine
 
 
 
Opioid agonistsc
 
 
 
 
 
 
 
 
 
 
a SSNRI = selective serotonin norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant.
b Consider lower starting dosages and slower titration in geriatric patients.
c First-line only in certain circumstances (see text).
d Consider lower starting dosages and slower titration in geriatric patients; dosages given are for short-acting formulation.
From Pain,12 with permission of the International Association for the Study of Pain® (IASP®). This table cannot be reproduced for any other purpose 
without permission.

No maximum dosage with careful 
  titration; consider evaluation by
  pain specialist at relatively high
  dosages (eg, morphine at
  120-180 mg/d; equianalgesic
  dosages should be used for other 
  opioid analgesics)
400 mg/d (100 mg 4 times daily); in 
  patients >75 y, 300 mg/d

After 1-2 wk, convert 
  total daily dosage to 
  long-acting opioid 
  analgesic and continue 
  short-acting medication 
  as needed 
 
Increase by 50-100 mg/d 
  in divided doses every  
  3-7 d as tolerated

3600 mg/d (1200 mg 3 times daily);  
  reduce if impaired renal function 
 
 
600 mg/d (200 mg 3 times 
  or 300 mg twice daily); reduce if
  impaired renal function

  methadone, and  
  levorphanolb 
 
 
 
 

  Morphine, oxycodone,  
 
 
 
 
 
 
  Tramadold 
 
 

 
 
 
 

10-15 mg morphine 
  every 4 h or as needed 
  (equianalgesic  
  dosages should be  
  used for other opioid  
  analgesics) 
 
50 mg once or twice  
  daily 
 

Increase by 100-300 mg 
  3 times daily every 
  1-7 d as tolerated 
 
Increase to 300 mg/d 
  after 3-7 d, then by 
  150 mg/d every 3-7 d 
  as tolerated

3-8 wk for  
  tritration plus 
  2 wk at
  maximum dose
4 wk

Maximum of 3 patches 
  daily for a maximum 
  of 12 h

Maximum of 3 patches daily for a 
  maximum of 12-18 h 

  5% lidocaine patch 
 
 

 
 

 
 

None needed 
 

 

3 wk
 

 

 

 

 

 

4-6 wk

4 wk

 
 

 
 

 
 

 

 

increases  until  pain  relief,  dose-limiting  adverse  effects, 
or 3600 mg/d in 3 divided doses is reached (Table 2). An 
adequate  trial  of  treatment  with  gabapentin  can  require  2 
months or more.
  The efficacy and tolerability of pregabalin seem to be 
similar to those of gabapentin; however, pregabalin has lin-
ear pharmacokinetics, and dosing is more straightforward. 
Most patients can start taking the drug at 150 mg/d in 2 or 
3 divided doses, which is then titrated up to 300 mg/d after 
1 or 2 weeks (Table 2). For patients who tolerate 300 mg/d 
but have inadequate pain relief, the dosage can be further 
titrated to 600 mg/d, but higher dosages are not consistent-
ly  more  effective  than  300  mg/d  and  are  associated  with 
a  greater  rate  of  adverse  effects.  Pregabalin  may  provide 
analgesia more quickly than gabapentin because the initial 

dosage  of  150  mg/d  has  been  found  to  be  efficacious  in 
some trials and because the time required to titrate to a full 
dosage is less.28 In the United States, pregabalin is a Sched-
ule V drug.
  Topical Lidocaine. The 5% lidocaine patch has shown 
efficacy  and  excellent  tolerability  in  RCTs  involving  pa-
tients  with  PHN  and  allodynia  and  in  patients  with  allo-
dynia due to different types of peripheral NP.12,21 As a topi-
cal treatment without substantial systemic absorption, the 
most common adverse effects are mild local reactions; the 
lack of systemic adverse effects and drug interactions can 
be  particularly  advantageous  in  older  patients  or  patients 
with complex NP (Table 2). Lidocaine gel (5%), which is 
less expensive than the lidocaine patch, has also shown ef-
ficacy in patients with PHN and allodynia.12,21 Topical li-

S6

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

docaine is most appropriate in well-localized NP, and it is 
unlikely to be of benefit in patients with central NP; unfor-
tunately, attempts to predict which patients are most likely 
to  respond  to  treatment  with  topical  lidocaine  have  been 
generally unsuccessful.29,30

SECOND-LINE MEDICATIONS THAT ARE APPROPRIATE FOR 
FIRST-LINE USE IN CERTAIN CIRCUMSTANCES 
Tramadol  and  opioid  analgesics  have  shown  efficacy  in 
several high-quality RCTs involving patients with different 
types of NP. Nevertheless, as a result of concerns regarding 
their long-term safety relative to the first-line medications, 
the NeuPSIG guidelines recommend that tramadol and opi-
oids should typically be reserved for patients who have not 
responded to first-line medications. However, these medi-
cations  are  recommended  as  first-line  treatments  for  pa-
tients with acute NP, NP due to cancer, and episodic exac-
erbations of severe NP, as well as when titrating one of the 
first-line medications if prompt relief of pain is required.
  Tramadol.    Tramadol,  which  has  shown  efficacy  in 
several NP conditions, is a weak opioid μ-receptor agonist 
that also inhibits reuptake of serotonin and norepinephrine. 
Like strong opioid analgesics, it provides relatively rapid 
pain relief, although it may be somewhat less efficacious 
than  strong  μ-agonists  (eg,  morphine  and  oxycodone).21 
The risk of abuse with tramadol seems considerably less 
than that with opioid analgesics.12
  The adverse effect profile of tramadol is similar to that 
of opioids, but tramadol also lowers the seizure threshold 
and can interact with certain medications (eg, SSNRIs and 
selective  serotonin  reuptake  inhibitors  [SSRIs])  to  cause 
serotonin syndrome, a potentially fatal reaction. Although 
the  risk  of  serotonin  syndrome  is  important  to  consider, 
it  appears  to  be  relatively  uncommon  in  clinical  practice. 
Treatment with tramadol is typically started at 50 mg once 
or twice daily and then increased gradually as needed to a 
maximum of 400 mg/d; older patients and those with renal 
or hepatic dysfunction are more prone to drug accumulation 
and should be maintained with lower dosages (Table 2).
  Opioid Analgesics. Several RCTs have shown that opi-
oid analgesics provide greater pain relief than placebo in 
different types of NP,12,21,31 with analgesia at least as great 
as that found with TCAs and gabapentin.32 However, be-
cause  of  concerns  regarding  long-term  safety,  including 
risks of hypogonadism, immunologic changes, and opioid 
misuse or abuse, opioids are not recommended for routine 
first-line use and should generally be reserved for patients 
who do not respond to the first-line medications discussed 
herein.
  Constipation,  nausea,  and  sedation  are  the  most  com-
mon  adverse  effects  of  opioids.  Initiating  treatment  with 
low dosages and titrating gradually can reduce nausea and 

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

sedation. However, constipation tends to be a chronic prob-
lem  for  patients  taking  opioids  and  should  be  monitored 
closely  and  treated  with  a  bowel  regimen. Various  thera-
peutic  strategies  are  emerging  that  have  the  potential  to 
mitigate opioid-associated constipation that require further 
evaluation. All patients treated with long-term opioid ther-
apy develop physical dependence; therefore, it is important 
to taper dosages gradually when treatment is being discon-
tinued and to instruct patients not to abruptly stop taking 
their medication.
  Patients with active or previous substance abuse (includ-
ing alcoholism) and a family history of substance abuse are 
more  likely  to  misuse  and  abuse  opioids.  This  risk  must 
be considered before treatment with an opioid analgesic is 
initiated;  opioid-prescribing  guidelines  recommend  using 
the lowest effective dosage and monitoring for signs of inap-
propriate use.33-35 Because the optimal opioid dosage varies 
substantially from patient to patient, patients must undergo 
individualized  opioid  titration,  using  dosages  that  have 
shown  efficacy  in  NP  trials  and  typically  using  extended-
release formulations for long-term treatment (Table 2).

THIRD-LINE MEDICATIONS
Several  additional  medications  have  shown  efficacy  for 
the  treatment  of  NP  in  either  a  single  RCT  or  inconsis-
tently  across  multiple  RCTs.  The  NeuPSIG  guidelines 
recommend  that  these  medications  should  generally  be 
reserved  for  patients  who  cannot  tolerate  or  who  do  not 
respond adequately to first- and second-line medications. 
These medications include certain antidepressant medica-
tions (eg, bupropion, citalopram, and paroxetine), certain 
antiepileptic medications (eg, carbamazepine, lamotrigine, 
oxcarbazepine, topiramate, and valproic acid), topical low-
concentration  capsaicin,  dextromethorphan,  memantine, 
and mexiletine.12

CENTRAL NP 
Relatively few RCTs have been conducted in patients with 
NP caused by lesions in the central nervous system, and re-
sults of these trials and clinical experience suggest that such 
conditions may be relatively more refractory to treatment 
than peripheral NP.21,36 Efficacy has been shown for TCAs 
in central poststroke NP, calcium channel α2-δ ligands in 
spinal cord injury and central poststroke NP, and tramadol 
in spinal cord injury NP.12,21,37,38 Cannabinoids appear to be 
efficacious in multiple sclerosis–associated NP, but use of 
cannabinoids is limited by poor availability and concerns 
regarding  risks  of  abuse  and  potential  to  precipitate  psy-
chosis,  especially  in  high-risk  individuals.12,39,40  Patients 
with  central  NP  who  do  not  respond  adequately  to  these 
medications can be treated with the first- and second-line 
medications that have established efficacy in peripheral NP 

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S7

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

(except  for  topical  lidocaine,  which  is  not  recommended 
for use in central NP).

RECENT CLINICAL TRIALS 

In this section, we briefly discuss several recent RCTs that 
should be considered in future efforts to revise the treat-
ment guidelines summarized herein. These studies do not 
represent a comprehensive update of recent NP trials but 
rather have been selected because they involve novel treat-
ments or provocative issues.

BOTULINUM TOXIN 
Efficacy  of  botulinum  toxin  in  the  treatment  of  cervical 
dys tonia and various types of spasticity is well established, 
but results of preclinical and human experimental studies41 
have suggested that it might also have an analgesic effect 
in patients with NP. On the basis of this research and an-
ecdotal observations, a double-blind trial was conducted in 
which 29 patients with PHN or posttraumatic or postopera-
tive NP and mechanical allodynia were randomized to in-
tradermal injection of botulinum toxin type A or matching 
placebo within the area of allodynia.42 Pain intensity dur-
ing 24 weeks and brush-evoked allodynia at 4 and 12 weeks 
after  treatment  were  significantly  reduced  in  patients  who 
received botulinum toxin vs placebo. In addition, a crossover 
trial of intradermal botulinum toxin injections into the feet 
of 20 patients with DPN showed significant pain reduction 
vs placebo during a 12-week period.43
  However,  in  a  randomized  trial  in  which  117  patients 
with  PHN  received  either  botulinum  toxin  or  placebo  and 
were followed up for 12 weeks, the 2 treatment groups did 
not  significantly  differ  (Susan  Abu-Shakra,  MD,  written 
communication, October 14, 2009). It is difficult to interpret 
the conflicting findings of 2 small trials showing efficacy and 
an unpublished multicenter trial that failed to demonstrate 
efficacy. The mean dose of botulinum toxin per area of pain 
in the negative PHN trial was lower than the dose used in the 
positive  PHN  or  posttraumatic  or  postoperative  NP  trial,42 
and it is possible that this accounts for the different results. 
As discussed herein, the increasing number of negative trials 
of NP treatments will make it challenging to update guide-
lines for the pharmacological management of NP.

HIGH-CONCENTRATION CAPSAICIN PATCH 
Topical low-concentration capsaicin is currently considered 
a third-line treatment of NP. A high-concentration capsa icin 
patch  has  been  studied  in  multiple  RCTs  in  patients  with 
PHN and painful HIV neuropathy.44 Results of 2 phase 3 tri-
als in PHN showed that a single application of the high-con-
centration  patch  vs  a  low-concentration  control  patch  was 
efficacious in reducing pain from the second week after the 

capsaicin  application  throughout  a  subsequent  8-week  pe-
riod; this effect was also observed for 12 weeks in secondary 
analyses.45,46 Similarly, 1 of 2 RCTs in patients with painful 
HIV neuropathy showed significantly decreased pain con-
tinuing from the second week after treatment through the 
end of a 12-week period.47 However, in a second HIV neu-
ropathy trial, the effects of high-concentration vs control 
patches did not significantly differ.44
  Application of the high-concentration capsaicin patch 
in patients with PHN or painful HIV neuropathy was safe 
and  well  tolerated,  and  adverse  events  were  limited  to 
transient  increases  in  pain  associated  with  patch  appli-
cation  and  application  site  reactions  (eg,  erythema).44-47 
Because a single treatment application may be associated 
with sustained reductions in pain that persists for 2 to 3 
months,  the  high-concentration  capsaicin  patch  has  the 
potential to provide a novel addition to existing pharma-
cological treatments for NP, which are typically adminis-
tered one or more times each day. However, the long-term 
benefits  of  this  treatment  are  unknown,  and  the  safety 
of repeated applications of high-concentration capsaicin 
must be carefully evaluated because skin biopsy studies 
have  shown  transient  epidermal  denervation  by  capsa-
icin48 that is paralleled by a functional loss, particularly 
of heat pain sensation.49

LACOSAMIDE 
Lacosamide is a new antiepileptic medication that has ac-
tivity at voltage-gated sodium channels. In addition to epi-
lepsy, lacosamide has been studied extensively in painful 
DPN.  Evidence  of  the  efficacy  of  lacosamide  in  patients 
with  painful  DPN  has  been  provided  by  the  results  of  a 
single  phase  2  trial,50  3  parallel  group  phase  3  trials,51-53 
and  a  randomized  withdrawal  trial  conducted  in  patients 
who  had  been  taking  lacosamide  on  an  open-label  basis 
for at least 1 year.54 In one of the later trials, the statistical 
significance of the result was marginal (P=.0507),51 and a 
fourth phase 3 trial failed to show a statistically significant 
difference between lacosamide and placebo.55
  Despite its approval for adjunctive treatment of partial-
onset seizures, lacosamide was not approved for the treat-
ment of painful DPN by either the Food and Drug Admin-
istration or the European Medicines Agency. It is unknown 
whether these negative decisions were based on inadequate 
evidence of efficacy—perhaps when a more conservative 
baseline observation carried forward strategy was used to 
impute  missing  data  for  individuals  who  withdrew  from 
the trials56—or whether concerns about safety provide the 
explanation. Although the safety and tolerability of lacos-
amide  appear  generally  comparable  to  other  medications 
approved  for  NP,  small  dose-related  increases  in  the  PR 
interval have been associated with lacosamide treatment.55  

S8

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

It  will  be  difficult  to  determine  what  recommendations 
should  be  made  for  lacosamide  in  future  NP  treatment 
guidelines  without  knowledge  of  the  specific  reasons  for 
the 2 negative regulatory decisions regarding its approval 
for the treatment of painful DPN. In the United States, la-
cosamide is a Schedule V drug.

SELECTIVE SEROTONIN REUPTAKE INHIBITORS
As  previously  mentioned,  SSRIs  have  been  considered 
third-line  medications  for  patients  with  NP.  This  is  be-
cause the evidence of the analgesic efficacy of this class 
of antidepressants has been inconsistent, with early cross-
over trials in patients with painful DPN showing modest 
beneficial effects for paroxetine58 and citalopram59 but no 
efficacy for fluoxetine60 compared with placebo. A recent 
crossover  RCT  in  patients  with  various  types  of  pain-
ful  polyneuropathy,  including  painful  DPN,  found  sig-
nificantly greater pain relief with escitalopram compared 
with placebo, a benefit that appeared to be independent of 
antidepressant effects.61 However, the authors concluded 
that  escitalopram  “appears  to  have  a  clinically  relevant 
effect  in  only  few  patients  and  …  can  probably  not  be 
recommended as first or second line treatment in neuro-
pathic pain.”61(p281)
 
It is well known that within several years after their in-
troduction, SSRIs began to replace TCAs in psychiatry as 
first-line medications for the treatment of depression. Un-
doubtedly, many reasons exist for this, including greater 
safety  against  overdose,  the  lack  of  a  need  for  titration 
in many patients because the starting dosage can be the 
therapeutic dosage, and an adverse effect profile that was 
often  preferable  to  that  associated  with TCAs.  Many  of 
these  differences  between  SSRIs  and TCAs  can  also  be 
relevant in the treatment of NP. For this reason, results of 
the 3 positive trials in painful polyneuropathies provide 
an impetus not only for a careful reevaluation of the role 
of SSRIs in NP but also for well-designed RCTs of their 
efficacy in additional NP conditions, ideally in head-to-
head  trials  directly  comparing  them  with  existing  first-
line treatments.

COMBINATION THERAPIES 
Most RCTs of treatments for NP have studied the effects 
of individual medications in specific conditions. However, 
as indicated earlier, no one medication is universally ef-
fective. Moreover, in most cases the medications we have 
discussed provide only partial pain relief, and adverse ef-
fects may limit dose escalation. Hence, in clinical prac-
tice, 2 or more medications are often used in combination 
to possibly achieve either an additive beneficial effect or 
a reduction in the adverse effects associated with the use 
of a single medication. Such a treatment paradigm makes 

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

intuitive sense, particularly if the medications act at dif-
ferent sites in pain signaling pathways or modulate dif-
ferent neurotransmitter systems. However, until recently 
little evidence was available to support the use of multiple 
medications in combination for the treatment of patients 
with NP.
 
In  one  of  the  first  RCTs  of  combination  therapy  for 
NP, the combination of gabapentin and extended-release 
morphine titrated together required lower dosages of both 
medications and resulted in better pain relief than when 
either  medication  was  administered  alone  in  patients 
with  PHN  or  painful  DPN.62  However,  results  failed  to 
show a beneficial effect of the combination with respect 
to  medication-related  adverse  effects.  Generally  consis-
tent results were obtained in a trial in which patients with 
painful DPN were randomized to receive either extended-
release  oxycodone  or  matching  placebo  in  combination 
with existing gabapentin treatment63; however, results of 
a recent trial showed no additional benefit of a low dosage 
of 10 mg/d of oxycodone vs placebo when combined with 
pregabalin.64 In an open-label prospective cohort study of 
403 patients with NP, the combination of extended-release 
oxycodone and pregabalin showed improved pain relief at 
lower dosages than either medication alone and was as-
sociated with improved HRQoL and better tolerability.65
  Recent RCTs have examined the combination of nor-
triptyline and gabapentin,66 which was superior to either 
of these 2 medications administered alone, as well as the 
combinations of pregabalin and topical 5% lidocaine67 and 
sodium  valproate  and  glyceryl  trinitrate  spray.68  Results 
of several trials that allowed patients to continue existing 
pharmacological treatments throughout double-blind eval-
uations of investigational medications provide additional 
evidence  that  combination  therapies  may  have  a  role  in 
the treatment of NP. For example, in several placebo-con-
trolled trials of pregabalin in PHN, patients were allowed 
to continue treatment with opioids, TCAs, and other med-
ications they were taking before inclusion in the study.69 
The  beneficial  effects  of  pregabalin  compared  with  pla-
cebo were comparable in patients who were and were not 
taking concomitant analgesics, suggesting that additional 
benefit was obtained when pregabalin was administered 
to patients already taking stable concomitant analgesics. 
A generally similar pattern of findings occurred in RCTs 
of high-concentration capsaicin discussed previously, in 
which patients were also allowed to continue their exist-
ing analgesics at stable dosages.44-47 However, a random-
ized crossover study of morphine, nortriptyline, and their 
combination  in  patients  with  lumbosacral  radiculopathy 
failed to showed a beneficial effect of either the combina-
tion or the medications administered alone (although this 
might be a relatively refractory chronic pain condition).70 

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S9

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

Additional  studies  are  needed  to  develop  guidelines  for 
identifying specific combinations of medications and the 
patients  who  obtain  the  greatest  benefits  from  rational 
polypharmacy.

NEGATIVE TRIALS OF PHARMACOLOGICAL  

TREATMENTS FOR NP AND THEIR INTERPRETATION 

An  increasing  number  of  RCTs  have  failed  to  show  sig-
nificant  differences  in  primary  efficacy  analyses  compar-
ing groups treated with a medication for NP and placebo, 
despite previous preclinical and clinical studies suggesting 
that efficacy would be expected.71-77 It is unclear whether 
these results reflect a true lack of efficacy in the specific 
conditions studied or whether other factors have accounted 
for the lack of success in demonstrating efficacy (eg, inad-
equate  power  to  detect  modest  treatment  benefits,  exces-
sive response rates in placebo groups, other methodologi-
cal features of the trials).
  Although  most  RCTs  of  pharmacological  treatments 
for NP have examined either PHN or painful DPN, the ex-
tent to which results of RCTs in these 2 conditions apply 
to  other  types  of  NP  is  unknown.  Moreover,  most  novel 
medications  are  validated  in  animal  models  of  traumatic 
neuropathy, whereas the evidence of NP efficacy is based 
on PHN, painful DPN, and other peripheral neuropathies.78  
Nevertheless, extrapolation of efficacy from first-line medi-
cations that have shown efficacy in one or more types of NP 
to other types of NP has seemed plausible, and medications 
that have shown efficacy in several different NP conditions 
may  have  the  greatest  probability  of  being  efficacious  in 
additional, as yet unstudied, conditions.12,79
  The  results  of  some  negative  trials,  however,  suggest 
that there may be types of NP that are less likely to respond 
to existing first-line treatments than PHN and painful DPN. 
The first indication of this was the publication in 1998 of 
2 placebo-controlled RCTs in which amitriptyline failed to 
relieve  pain  in  patients  with  painful  HIV  neuropathy,80,81 
which has been followed by negative trials of topical lido-
caine82 and pregabalin76 in HIV neuropathy. The results of a 
recent negative trial of memantine in HIV neuropathy83 are 
more difficult to interpret because memantine is considered 
a third-line NP treatment on the basis of inconsistent evi-
dence of efficacy.12 Therefore, these negative results may 
reflect either minimal efficacy of memantine in NP or lack 
of efficacy in an NP condition (HIV neuropathy) that ap-
pears generally refractory to treatment (but that has been 
shown to respond to at least one treatment, high-concentra-
tion capsaicin).47
  Chemotherapy-induced  peripheral  neuropathy  may  be 
another NP condition that is relatively refractory to exist-
ing first-line treatments. In 3 RCTs, there was no evidence 

of  efficacy  of  nortriptyline,84  amitriptyline,85  or  gabapen-
tin.86  Finally,  recent  trials  of  nortriptyline  and  morphine 
and their combination70 and pregabalin87 and an equivocal 
trial of topiramate88 suggest that lumbosacral radiculopathy 
might be a third peripheral NP condition that is relatively 
refractory  to  existing  first-  and  second-line  medications. 
Interestingly, patients with failed back surgery syndrome, 
many of whom have lumbosacral radiculopathy, appear to 
respond  to  spinal  cord  stimulation,89  which  suggests  that 
this  NP  condition  is  not  generally  refractory  to  all  treat-
ment modalities.
  Of course, these negative RCTs of HIV-asociated neurop-
athy,  chemotherapy-induced  neuropathy,  and  lumbosacral 
radiculopathy  may  have  had  methodological  features  that 
compromised their ability to demonstrate efficacy. However, 
the consistency of the negative results suggests that medica-
tions  with  established  efficacy  in  the  most  prevalent  pain-
ful polyneuropathy (painful DPN) might not have efficacy 
in other painful polyneuropathies, and, more generally, that 
it cannot be assumed that evidence of efficacy in one or two 
NP conditions can be extrapolated to others.
 
In  addition  to  raising  challenging  questions  about  the 
extrapolation  of  efficacy,  the  negative  results  of  recent 
RCTs make it difficult to determine the role of treatments 
in NP guidelines. Such recent developments as evidence of 
efficacy from several small RCTs combined with negative 
results  from  larger  phase  3  trials,  as  well  as  positive  and 
negative trials that have not provided an adequate basis for 
regulatory  approval,  are  challenging  to  interpret  and  will 
require careful consideration in revising existing treatment 
guidelines.
 
Importantly, negative results of recent RCTs of NP and 
other chronic pain conditions have focused attention on the 
research methods used in chronic pain trials.90-94 It can be 
hoped that this increased attention to clinical trial research 
designs  will  lead  to  methodological  innovations  that  im-
prove assay sensitivity and reduce the number of negative 
trials of truly efficacious medications (ie, so-called failed 
trials).

CONCLUSION 

Diverse  pharmacological  treatments  of  NP  have  become 
available,  and  interpreting  the  data  on  their  efficacy  and 
safety  involves  substantial  complexities  and  ambiguities. 
In updating the NeuPSIG pharmacological guidelines for 
the management of NP, a multifactorial evaluation will be 
required that carefully considers the clinical importance of 
the improvements shown by patients and the benefits and 
risks of each treatment in view of the other available treat-
ments for NP95-97 (Table 3). In the meantime, improved ad-
herence to existing treatment guidelines is needed.6,12-14

S10

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

 TABLE 3. Factors to Consider in Determining the Clinical  

Meaningfulness of Group Differences

Statistical significance of the primary efficacy analysis (typically  
  necessary but not sufficient to determine that the group difference is  
  clinically meaningful)
Magnitude of improvement in the primary efficacy outcome with treatment
Results of responder analyses
Treatment effect size compared with available treatments
Rapidity of onset of treatment benefit
Durability of treatment benefit
Results for secondary efficacy end points (eg, improvements in physical  
  and/or emotional functioning)
Safety and tolerability
Convenience
Patient adherence
Cost
Different mechanism of action vs existing treatments
Limitations of available treatments
Other benefits (eg, few or no drug interactions, availability of a test that  
  predicts a good therapeutic response)
From  Pain,97  with  permission  of  the  International  Association  for  the 
Study of Pain® (IASP®). This table cannot be reproduced for any other 
purpose without permission.

  To provide a superior evidence base for future treatment 
guidelines, additional RCTs must be conducted in which 
existing NP medications are directly compared with each 
other98-102 and administered in various combinations. In ad-
dition, increased efforts must be devoted to identifying new 
medications that show greater magnitudes of pain reduc-
tion, clinically meaningful pain relief in higher percentages 
of  patients,  better  tolerability  and  safety,  greater  benefits 
on physical and emotional functioning, few or no drug in-
teractions, and greater patient convenience and adherence. 
Future treatment guidelines will need to consider whether 
other approaches for the management of patients with NP 
(eg, physical therapy, spinal cord stimulation, and psycho-
social interventions) should be used before, in combination 
with,  or  after  pharmacological  treatments.103  Traditional 
RCTs may ultimately not be the method of choice to an-
swer  all  these  questions104;  alternative  approaches  should 
be  developed  and  evaluated  (eg,  systematic  comparative 
effectiveness studies of health care registry data).
It has become commonplace to conclude articles on the 
 
pharmacological  treatment  of  NP  by  emphasizing  either 
the public health benefits of identifying interventions that  
prevent NP or the importance of developing mechanism-
based treatment approaches. One recent major advance is 
the widespread availability of a vaccine that halves the risk 
of herpes zoster in individuals older than 60 years and in so 
doing prevents PHN.105 Unfortunately, attention paid to de-
veloping preventive interventions for other NP conditions 
has been limited.106 In contrast, the prospects for developing 
a mechanism-based approach to the treatment of NP seem 
promising.107,108 Although  important  challenges  remain,109 
research groups in Germany,110,111 the United States,112 and 

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

elsewhere  are  now  systematically  identifying  patterns  of 
NP symptoms and signs that appear to correspond to un-
derlying pathophysiologic mechanisms. Given the diverse 
mechanisms of action of the medications discussed in this 
article, these programs of research provide a basis for con-
siderable optimism that future treatment guidelines for NP 
will be able to specify what medications are most effective 
for which types of patients.107,113

(cid:56)(cid:70)(cid:1)(cid:85)(cid:73)(cid:66)(cid:79)(cid:76)(cid:1)(cid:49)(cid:66)(cid:86)(cid:77)(cid:1)(cid:43)(cid:15)(cid:1)(cid:45)(cid:66)(cid:78)(cid:67)(cid:74)(cid:66)(cid:84)(cid:70)(cid:1)(cid:71)(cid:80)(cid:83)(cid:1)(cid:68)(cid:80)(cid:80)(cid:83)(cid:69)(cid:74)(cid:79)(cid:66)(cid:85)(cid:74)(cid:79)(cid:72)(cid:1)(cid:85)(cid:73)(cid:70)(cid:1)(cid:78)(cid:70)(cid:70)(cid:85)(cid:74)(cid:79)(cid:72)(cid:1)(cid:80)(cid:79)(cid:1)(cid:88)(cid:73)(cid:74)(cid:68)(cid:73)(cid:1)
(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:70)(cid:78)(cid:70)(cid:79)(cid:85)(cid:1)(cid:74)(cid:84)(cid:1)(cid:67)(cid:66)(cid:84)(cid:70)(cid:69)(cid:15)(cid:1)

Individual Disclosures for Authors: Dr Dworkin has received 
in the past 12 months research support from Arcion, Montel Wil-
liams Foundation, and NeurogesX and consulting fees from Aller-
gan, Astellas, AstraZeneca, Boehringer Ingelheim, Durect, Eisai, 
Endo  Pharmaceuticals,  Epicept,  Forest,  Genzyme,  Johnson  & 
Johnson, Eli Lilly, Michael J. Fox Foundation for Parkinson’s Re-
search, NeurogesX, Nuvo, Pfizer, PainReform, Philips Respiron-
ics, Sanofi Aventis, Solace, Solvay, Spinifex, UCB Pharma, US 
Department of Veterans Affairs, US National Institutes of Health, 
Wyeth, and Xenon; Dr O’Connor has no financial arrangement 
or affiliation with a corporate organization or a manfacturer of a 
product discussed in this supplement; Dr Audette has served on 
the  speakers’  bureau  for  Allergan,  Endo  Pharmaceuticals,  and 
Johnson & Johnson; Dr Baron has received grant/research support 
from  Pfizer  Pharma,  Genzyme,  and  Grünenthal  and  has  served 
on the  speakers’ bureau and as a consultant for Pfizer Pharma, 
Genzyme,  Grünenthal,  Mundipharma, Allergan,  Sanofi  Pasteur, 
Astellas, Eisai, Medtronic, USB, and Eli Lilly; Dr. Gourlay has 
no financial arrangement or affiliation with a corporate organiza-
tion or a manfacturer of a product discussed in this supplement; 
Dr Haanpää has served as consultant for Boehringer Ingelheim, 
GlaxoSmithKline,  Eli  Lilly,  Medtronic,  MSD,  Mundipharma, 
Orion,  Pfizer,  and  Sanofi  Pasteur  and  is  a  permanent  assessor 
of  EMEA;  Dr  Kent  has  received  grant/research  support  from 
GlaxoSmithKline  and  has  served  on  the  speakers’  bureau  for 
Medtronic; Dr Krane has no financial arrangement or affiliation 
with a corporate organization or a manfacturer of a product dis-
cussed in this supplement; Dr LeBel has no financial arrangement 
or  affiliation  with  a  corporate  organization  or  a  manfacturer  of 
a  product  discussed  in  this  supplement;  Dr  Levy  has  received 
grant/research support from St. Jude Medical Neuromodulation, 
has served as a consultant for Bioness, Codman, Medtronic, St 
Jude Medical Neuromodulation, and Stryker; Dr Mackey has no 
financial arrangement or affiliation with a corporate organization 
or a manfacturer of a product discussed in this supplement; Dr 
Mayer has received grant/research support from Johnson & John-
son and is on the Clinical Advisory Board for Palladian Health; 
Dr Miaskowski has no financial arrangement or affiliation with 
a corporate organization or a manfacturer of a product discussed 
in this supplement; Dr Raja has received grant/research support 
from Allergan and Medtronic and served as a consultant for Al-
lergan, Alpharma (King), Schering-Plough, and Solvay; Dr Rice 
has received grant/research support from Pfizer and Spinifex and 
has served as a consultant for Pfizer, Allergen, Astellas, Daiichi 

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S11

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

Sankyo,  GlaxoSmithKline,  NeurogesX,  Spinifex,  and  Eisia;  Dr 
Schmader  has  received  grant/research  support  from  Merck  and 
Wyeth  and  has  served  as  a  consultant  for  Merck  and  Glaxo-
SmithKline; Dr Stacey has received grant/research support from 
AstraZeneca and has served as a consultant for GlaxoSmithKline, 
Boehringer Ingelheim, Boston Scientific, Eli Lilly, Niktar, QRX 
Pharma, Pfizer, AstraZeneca, and Xenon; Dr Stanos has received 
grant/research  support  from  Ortho-McNeil;  has  served  as  a 
consultant  for  Abbott  Labs,  Eli  Lilly,  Endo  Pharmaceuticals, 
King,  and  Ortho-McNeil;  and  is  on  the  speakers’  bureau  for 
Endo  Pharmaceuticals,  Eli  Lilly,  Ortho-McNeil,  Pfizer,  King, 
and Forest; Dr Treede has received grant/research support from 
Kade and Boehringer Ingelheim and has served as a consultant 
for Grünenthal, UCB, AWD pharma, GmbH & Co, and Kade; 
Dr Turk  has  received  grant/research  support  from  Endo  Phar-
maceuticals,  Johnson  &  Johnson,  and  Philips  Respironics  and 
has  served  as  a  consultant  for  Eli  Lilly,  Johnson  &  Johnson, 
Philips Respironics, and SK Lifescience; Dr Walco has served 
as  a  consultant  for  Neuromed,  Pfizer,  and  Purdue  Pharma;  Dr 
Wells has served as a consultant for Prostrachan and is on the 
speakers’  bureau  for  Grünenthal,  Napp  (Purdue  in  the  United 
States), and Pfizer.

 REFERENCES
1.  Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefini-
 
tion and a grading system for clinical research purposes. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2008; 
70(18):1630-1635.
 
2.  Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication 
use, and health-related quality of life in older persons with postherpetic neu-
ralgia: results from a population-based survey. (cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2005;6(6):356-363.
 
3.  Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of 
illness in painful diabetic peripheral neuropathy: the patients’ perspectives. (cid:43)(cid:1)
Pain. 2006;7(12):892-900.
 
4.  McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. 
The  burden  of  neuropathic  pain:  results  of  a  cross-sectional  survey.  (cid:38)(cid:86)(cid:83)(cid:1) (cid:43)(cid:1)
Pain. 2006;10(2):127-135.
 
5.  Jensen  MP,  Chodroff  MJ,  Dworkin  RH.  The  impact  of  neuropathic 
pain  on  health-related  quality  of  life:  review  and  implications.  (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
2007;68(15):1178-1182.
 
6.  O’Connor AB. Neuropathic pain: a review of the quality of life impact, 
costs,  and  cost-effectiveness  of  therapy.  (cid:49)(cid:73)(cid:66)(cid:83)(cid:78)(cid:66)(cid:68)(cid:80)(cid:70)(cid:68)(cid:80)(cid:79)(cid:80)(cid:78)(cid:74)(cid:68)(cid:84).  2009;27(2): 
95-112.
 
7.  Berger A, Dukes EM, Oster G. Clinical characteristics and econom-
ic  costs  of  patients  with  painful  neuropathic  disorders.  (cid:43)(cid:1) (cid:49)(cid:66)(cid:74)(cid:79).  2004;5(3): 
143-149.
 
8.  Dworkin RH, White R, O’Connor AB, Baser O, Hawkins K. Health 
care costs of acute and chronic pain associated with a diagnosis of herpes 
zoster. (cid:43)(cid:1)(cid:34)(cid:78)(cid:1)(cid:40)(cid:70)(cid:83)(cid:74)(cid:66)(cid:85)(cid:83)(cid:1)(cid:52)(cid:80)(cid:68). 2007;55(8):1168-1175.
 
9.  Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Im-
pact of postherpetic neuralgia and painful diabetic peripheral neuropathy on 
health care costs [published online ahead of print October 21, 2009]. (cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 
doi:10.1016/j.jpain. 2009.08.005.
  10.  van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Esti-
mating the cost-effectiveness of vaccination against herpes zoster in England 
and Wales. (cid:55)(cid:66)(cid:68)(cid:68)(cid:74)(cid:79)(cid:70). 2009;27(9):1454-1467.
  11.  Donaldson Sir L. The 2008 report of the Chief Medical Officer:150 years 
of the Annual Report of the Chief Medical Officer: on the state of public health 
2008. London, England: Department of Health, 2009. http://www.dh.gov.uk 
/en/Publicationsandstatistics/Publications/AnnualReports/DH_096206.  Ac-
cessed January 12, 2010.
  12.  Dworkin  RH,  O’Connor  AB,  Backonja  M,  et  al.  Pharmacologic 
management  of  neuropathic  pain:  evidence-based  recommendations.  Pain. 
2007;132(3):237-251.

  13.  Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacolog-
ical treatment of neuropathic pain. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2006;13(11):1153-1169.
  14.  Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management 
of chronic neuropathic pain—consensus statement and guidelines from the 
Canadian Pain Society. (cid:49)(cid:66)(cid:74)(cid:79)(cid:1)(cid:51)(cid:70)(cid:84)(cid:1)(cid:46)(cid:66)(cid:79)(cid:66)(cid:72). 2007;12(1):13-21.
  15.  O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an over-
view of recent guidelines. (cid:34)(cid:78)(cid:1)(cid:43)(cid:1)(cid:46)(cid:70)(cid:69). 2009;122(10A):S22-S32.
  16.  Attal  N,  Fermanian  C,  Fermanian  J,  Lanteri-Minet  M,  Alchaar  H, 
Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the 
aetiology or anatomical lesion? Pain. 2008;138(2):343-353.
  17.  Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross sec-
tional cohort survey in 2100 patients with painful diabetic neuropathy and 
postherpetic neuralgia: differences in demographic data and sensory systems. 
Pain. 2009;146(1-2):34-40.
  18.  CEBM Centre for Evidence-based Medicine. CEBM Web site. Lev-
els of evidence and grades of recommendation. http://www.cebm.net/index 
.aspx?o=1025. Accessed January 12, 2010.
  19.  Cruccu  G,  Gronseth  G,  Alksne  J,  et  al.  AAN-EFNS  guidelines  on 
trigeminal neuralgia management. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2008;15(10):1013-1028.
  20.  Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnos-
tic evaluation and treatment of trigeminal neuralgia (an evidence-based review): 
report  of  the  Quality  Standards  Subcommittee  of  the American Academy  of 
Neurology and the European Federation of Neurological Socie ties. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
2008;71(15):1183-1190.
  21.  Finnerup  NB,  Otto  M,  McQuay  HJ,  Jensen  TS,  Sindrup  SH. Algo-
rithm  for  neuropathic  pain  treatment:  an  evidence  based  proposal.  Pain. 
2005;118(3):289-305.
  22.  Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves dia-
betic neuropathy pain in patients with normal or depressed mood. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
1987;37(4):589-596.
  23.  Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in 
the long-term management of diabetic peripheral neuropathic pain. (cid:43)(cid:1)(cid:49)(cid:66)(cid:77)(cid:77)(cid:74)(cid:66)(cid:85)(cid:1)
(cid:46)(cid:70)(cid:69). 2006;9(1):29-40.
  24.  Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascu-
lar safety profile of duloxetine: findings from 42 placebo-controlled studies. 
(cid:37)(cid:83)(cid:86)(cid:72)(cid:1)(cid:52)(cid:66)(cid:71). 2007;30(5):437-455.
  25.  McIntyre  RS,  Panjwani  ZD,  Nguyen  HT,  et  al.  The  hepatic  safe-
ty  profile  of  duloxetine:  a  review.  (cid:38)(cid:89)(cid:81)(cid:70)(cid:83)(cid:85)(cid:1) (cid:48)(cid:81)(cid:74)(cid:79)(cid:1) (cid:37)(cid:83)(cid:86)(cid:72)(cid:1) (cid:46)(cid:70)(cid:85)(cid:66)(cid:67)(cid:1) (cid:53)(cid:80)(cid:89)(cid:74)(cid:68)(cid:80)(cid:77). 
2008;4(3):281-285.
  26.  Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended re-
lease in the treatment of painful diabetic neuropathy: a double-blind, place-
bo-controlled study. Pain. 2004;110(3):697-706.
  27.  Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emer-
gence of adverse events following discontinuation of treatment with extend-
ed-release venlafaxine. (cid:34)(cid:78)(cid:1)(cid:43)(cid:1)(cid:49)(cid:84)(cid:90)(cid:68)(cid:73)(cid:74)(cid:66)(cid:85)(cid:83)(cid:90). 1997;154(12):1760-1762.
  28.  Stacey  BR,  Barrett  JA,  Whalen  E,  Phillips  KF,  Rowbotham  MC. 
Pregabalin  for  postherpetic  neuralgia:  placebo-controlled  trial  of  fixed  and 
flexible dosing regimens on allodynia and time to onset of pain relief. (cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 
2008;9(11):1006-1017.
  29.  Wasner G, Kleiner A, Binder A, Schattschneider J, Baron R. Posther-
petic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. (cid:43)(cid:1)
(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2005;252(6):677-686.
  30.  Herrmann DN, Pannoni V, Barbano RL, Pennella-Vaughan J, Dworkin 
RH.  Skin  biopsy  and  quantitative  sensory  testing  do  not  predict  response  to 
the lidocaine patch in painful neuropathies. (cid:46)(cid:86)(cid:84)(cid:68)(cid:77)(cid:70)(cid:1)(cid:47)(cid:70)(cid:83)(cid:87)(cid:70). 2006;33(1):42-48.
  31.  Wu CL, Agarwal S, Tella PK, et al. Morphine versus mexiletine for 
treatment of postamputation pain. (cid:34)(cid:79)(cid:70)(cid:84)(cid:85)(cid:73)(cid:70)(cid:84)(cid:74)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2008;109(2):289-296.
  32.  Raja  SN,  Haythornthwaite  JA,  Pappagallo  M,  et  al.  Opioids  versus 
antidepressants in postherpetic neuralgia: a randomized, placebo-controlled 
trial. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2002;59(7):1015-1021.
  33.  British Pain Society. Recommendations for the appropriate use of opi-
oids for persistent non-cancer pain. London, England: British Pain Society, 
2005.  http://www.britishpainsociety.org/opioids_doc_2004.pdf.  Accessed 
January 12, 2010.
  34.  Højsted J, Sjögren P. Addiction to opioids in chronic pain patients: a 
literature review. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2007;11(5):490-518.
  35.  Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use 
of  chronic  opioid  therapy  in  chronic  noncancer  pain.  (cid:43)(cid:1) (cid:49)(cid:66)(cid:74)(cid:79).  2009;10(2): 
113-130.

S12

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

  36.  Katz  J,  Finnerup  NB,  Dworkin  RH.  Clinical  trial  outcome  in  neuro  - 
  pathic pain: relationship to study characteristics. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2008;70(4):263- 
272.
  37.  Vranken JH, Dijkgraaf MGW, Kruis MR, van der Vegt MH, Hollmann 
MW, Heesen M. Pregabalin in patients with central neuropathic pain: a ran-
domized, double-blind, placebo-controlled trial of a flexible-dose regimen. 
Pain. 2008;136(1-2):150-157.
  38.  Norrbrink  C,  Lundeborg  T.  Tramadol  in  neuropathic  pain  after  spi-
nal cord injury: a randomized, double-blind, placebo-controlled trial. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:43)(cid:1)
Pain. 2009;25(3):177-184.
  39.  O’Connor AB,  Schwid  SR,  Markman  J,  Hermann  D,  Dworkin  RH. 
Pain associated with multiple sclerosis: systematic review and proposed clas-
sification. Pain. 2008;137(1):96-111.
  40.  Rice ASC. Should cannabinoids be used as analgesics for neuropathic 
pain? (cid:47)(cid:66)(cid:85)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:66)(cid:68)(cid:85)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2008;4(12):654-655.
  41.  Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A re-
duces capsaicin-evoked pain and neurogenic vasodilatation in human skin. 
Pain. 2007;130(1-2):76-83.
  42.  Ranoux  D, Attal  N,  Morain  F,  Bouhassira  D.  Botulinum  toxin  type 
A induces direct analgesic effects in chronic neuropathic pain. (cid:34)(cid:79)(cid:79)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:15) 
2008;64(3):274-284.
  43.  Yuan  RY,  Sheu  JJ, Yu  JM,  et  al.  Botulinum  toxin  for  diabetic  neu-
ropathic  pain:  a  randomized  double-blind  crossover  trial.  (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
2009;72(17):1473-1478.
  44.  European Medicines Agency. CHMP assessment report for Qutenza. 
http://www.emea.europa.eu/humandocs/PDFs/EPAR/Qutenza/H-909-en6.
pdf. Accessed January 12, 2010.
  45.  Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-con-
centration capsaicin patch, for the treatment of postherpetic neuralgia: a ran-
domised, double-blind study. (cid:45)(cid:66)(cid:79)(cid:68)(cid:70)(cid:85)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2008;7(12):1106-1112.
  46.  Qutenza  (NGX-4010):  Full  prescribing  information.  http://www 
.neurogesx.com/ngx_4010. Accessed January 12, 2010.
  47.  Simpson DM, Brown S, Tobias J. Controlled trial of high-concentra-
tion  capsaicin  patch  for  treatment  of  painful  HIV  neuropathy.  (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
2008;70(24):2305-2313.
  48.  Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffin JW, McArthur 
JC. The time course of epidermal nerve fibre regeneration: studies in normal 
controls  and  in  people  with  diabetes,  with  and  without  neuropathy.  Brain. 
2004;127(pt 7):1606-1615.
  49.  Magerl W, Fuchs PN, Meyer RA, Treede RD. Roles of capsaicin-in-
sensitive nociceptors in cutaneous pain and secondary hyperalgesia. Brain. 
2001;124(pt 9):1754-1764.
  50.  Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in 
painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-con-
trolled study. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2007;23(2):150-158.
  51.  Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabet-
ic  neuropathy:  an  18-week  double-blind  placebo-controlled  trial.  (cid:43)(cid:1) (cid:49)(cid:66)(cid:74)(cid:79). 
2009;10(8):818-828.
  52.  Wymer  JP,  Simpson  J,  Sen  D,  Bongardt  S.  Efficacy  and  safety  of  
lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-
controlled trial of fixed-dose regimens. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2009;25(5):376-385.
  53.  UCB, Inc. Clinical study summary (CSS) template, Study No. SP874. 
http://www.clinicalstudyresults.org/documents/company-study_8251_0.pdf. 
Accessed January 12, 2010.
  54.  Hidvégi T, Bretschneider B, Thierfelder S, Sommerville K, Bongardt S. 
Long-term  efficacy  of  lacosamide  in  subjects  with  diabetic  neuropathic  pain: 
results of a double-blind, randomized withdrawal trial. Presented at: 27th annual 
meeting of the American Pain Society; Tampa, FL; May 8-10, 2008.
  55.  UCB, Inc. Clinical study summary (CSS) template, Study No. SP743. 
http://www.clinicalstudyresults.org/documents/company-study_8250_0.pdf. 
Accessed January 12, 2010.
  56.  O’Connor AB. The need for improved access to FDA reviews. (cid:43)(cid:34)(cid:46)(cid:34). 
2009;302(2):191-193.
  57.  Shaibani A,  Biton V,  Rauck  R,  Koch  B,  Simpson  J.  Long-term  oral 
lacosamide in painful diabetic neuropathy: a two-year open-label extension 
trial. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2009;13(5):458-463.
  58.  Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selec-
tive  serotonin  reuptake  inhibitor  paroxetine  is  effective  in  the  treatment  of 
diabetic neuropathy symptoms. Pain. 1990;42(2):135-144.

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

  59.  Sindrup  SH,  Bjerre  U,  Dejgaard  A,  Brøsen  K,  Aaes-Jørgensen,  
Gram  LF.  The  selective  serotonin  reuptake  inhibitor  citalopram  relieves  the 
symptoms of diabetic neuropathy.(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:73)(cid:66)(cid:83)(cid:78)(cid:66)(cid:68)(cid:80)(cid:77)(cid:1)(cid:53)(cid:73)(cid:70)(cid:83). 1992;52(5):547-552.
  60.  Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects 
of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. 
(cid:47)(cid:1)(cid:38)(cid:79)(cid:72)(cid:77)(cid:1)(cid:43)(cid:1)(cid:46)(cid:70)(cid:69). 1992;326(19):1250-1256.
  61.  Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH. Escitalopram in 
painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. 
Pain. 2008;139(2):275-283.
  62.  Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Mor-
phine, gabapentin, or their combination for neuropathic pain. (cid:47)(cid:1)(cid:38)(cid:79)(cid:72)(cid:77)(cid:1)(cid:43)(cid:1)(cid:46)(cid:70)(cid:69). 2005; 
352(13):1324-1334.
  63.  Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone en-
hances the effects of existing gabapentin therapy in painful diabetic neuropa-
thy patients. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2008;12(6):804-813.
  64.  Zin CS, Nissen LM, O’Callaghan JP, Duffull SB, Smith MT, Moore 
BJ. A randomized controlled trial of oxycodone vs placebo in patients with 
postherpetic neuralgia and painful diabetic neuropathy treated with pregabal-
in [published online ahead of print December 2, 2009]. (cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79).  doi:10.1016/j.
jpain.2009.09.003.
  65.  Gatti A, Sabato AF, Occhioni R, Baldeschi GC, Reale C. Controlled-
release oxycodone and pregabalin in the treatment of neuropathic pain: re-
sults of a multicenter Italian study.(cid:1)(cid:38)(cid:86)(cid:83)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77). 2009;61(3):129-137.
  66.  Gilron  I,  Bailey  JM,  Tu  D,  Holden  RR,  Jackson AC,  Houlden  RL. 
Nortriptyline  and  gabapentin,  alone  and  in  combination  for  neuropathic 
pain:  a  double-blind,  randomised  controlled  crossover  trial.  (cid:45)(cid:66)(cid:79)(cid:68)(cid:70)(cid:85).  2009; 
374(9697):1252-1261.
  67.  Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Ef-
ficacy and safety of combination therapy with 5% lidocaine medicated plas-
ter  and  pregabalin  in  post-herpetic  neuralgia  and  diabetic  polyneuropathy. 
(cid:36)(cid:86)(cid:83)(cid:83)(cid:1)(cid:46)(cid:70)(cid:69)(cid:1)(cid:51)(cid:70)(cid:84)(cid:1)(cid:48)(cid:81)(cid:74)(cid:79). 2009;25(7):1677-1687.
  68.  Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic 
neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective 
double-blind randomized placebo-controlled study. (cid:37)(cid:74)(cid:66)(cid:67)(cid:70)(cid:85)(cid:70)(cid:84)(cid:1)(cid:51)(cid:70)(cid:84)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:66)(cid:68)(cid:85). 
2009;83(3):371-378.
  69.  Dworkin RH, Thakur R, Griesing T, Sharma U, Young JP. Randomized 
clinical trials of pregabalin for neuropathic pain: methods, results, and im-
plications. (cid:49)(cid:83)(cid:80)(cid:72)(cid:83)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:85)(cid:73)(cid:70)(cid:83)(cid:66)(cid:81)(cid:70)(cid:86)(cid:85)(cid:74)(cid:68)(cid:84)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:81)(cid:84)(cid:90)(cid:68)(cid:73)(cid:80)(cid:81)(cid:73)(cid:66)(cid:83)(cid:78)(cid:66)(cid:68)(cid:80)(cid:77). 2008;3(1):167- 
187.
  70.  Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and 
their combination vs. placebo in patients with chronic lumbar root pain. Pain. 
2007;130(1-2):66-75.
  71.  Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in pain-
ful diabetic polyneuropathy: findings from three double-blind placebo-con-
trolled trials. (cid:34)(cid:68)(cid:85)(cid:66)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:1)(cid:52)(cid:68)(cid:66)(cid:79)(cid:69). 2004;110(4):221-231.
  72.  Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in pain-
ful diabetic neuropathy: results of a dose-ranging study. (cid:34)(cid:68)(cid:85)(cid:66)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:1)(cid:52)(cid:68)(cid:66)(cid:79)(cid:69). 
2006;113(6):395-404.
  73.  Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, 
Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, 
crossover, pilot trial of lamotrigine in patients with central pain due to mul-
tiple sclerosis. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:53)(cid:73)(cid:70)(cid:83). 2007;29(9):2022-2030.
  74.  Silver M, Blum D, Grainger J, Hammer AE, Quessy S. Double-blind, 
placebo-controlled  trial  of  lamotrigine  in  combination  with  other  medica-
tions for neuropathic pain.(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79)(cid:1)(cid:52)(cid:90)(cid:78)(cid:81)(cid:85)(cid:80)(cid:78)(cid:1)(cid:46)(cid:66)(cid:79)(cid:66)(cid:72)(cid:70). 2007;34(4):446-454.
  75.  Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of 
pain associated with diabetic neuropathy: results of two randomized double-
blind, placebo-controlled studies. Pain. 2007;128(1-2):169-179.
  76.  Simpson  DM,  Schifitto  G,  Clifford  DB,  et  al;  1066  HIV  Neuropa-
thy Study Group. Pregabalin in the treatment of painful HIV neuropathy: a 
randomized, double-blind, placebo-controlled trial. Poster presented at: 61st 
Annual Meeting of the American Academy of Neurology, Seattle, WA; April 
29, 2009.
  77.  XenoPort, Inc. Phase II results for GSK1838262 (XP13512) reported 
for  neuropathic  pain  associated  with  diabetic  peripheral  neuropathy.  Santa 
Clara, CA: XenoPort, Inc; 2009.
  78.  Rice ASC, Cimino-Brown D, Eisenach JC, et al. Animal models and 
the prediction of efficacy in clinical trials of analgesic drugs: a critical ap-
praisal and call for uniform reporting standards. Pain. 2008;139(2):243-247.

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

S13

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN

  79.  Hansson PT, Dickenson AH. Pharmacological treatment of peripheral 
neuropathic conditions based on shared commonalities despite multiple eti-
ologies. Pain. 2005;113(3):251-254.
  80.  Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of 
amitriptyline and mexiletine for painful neuropathy in HIV infection. (cid:47)(cid:70)(cid:86)(cid:14)
(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 1998;51(6):1682-1688.
  81.  Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline 
for pain due to HIV-related peripheral neuropathy: a randomized controlled 
trial. (cid:43)(cid:34)(cid:46)(cid:34). 1998;280(18):1590-1595.
  82.  Estanislao L, Carter K, McArthur J, Olney R, Simpson D. A random-
ized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric 
polyneuropathy. (cid:43)(cid:1)(cid:34)(cid:68)(cid:82)(cid:86)(cid:74)(cid:83)(cid:1)(cid:42)(cid:78)(cid:78)(cid:86)(cid:79)(cid:70)(cid:1)(cid:37)(cid:70)(cid:224)(cid:68)(cid:1)(cid:52)(cid:90)(cid:79)(cid:69)(cid:83). 2004;37(5):1584-1586.
  83.  Schifitto G, Yiannoutsos CT, Simpson DM, et al. A placebo-controlled 
study of memantine for the treatment of human immunodeficiency virus-as-
sociated sensory neuropathy. (cid:43)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:87)(cid:74)(cid:83)(cid:80)(cid:77). 2006;12(4):328-331.
  84.  Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of 
nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral 
neuropathy. Pain. 2002;98(1-2):195-203.
  85.  Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treat-
ment  of  chemotherapy-induced  neuropathic  symptoms.  (cid:43)(cid:1) (cid:49)(cid:66)(cid:74)(cid:79)(cid:1) (cid:52)(cid:90)(cid:78)(cid:81)(cid:85)(cid:80)(cid:78)(cid:1)
(cid:46)(cid:66)(cid:79)(cid:66)(cid:72)(cid:70). 2008;35(1):31-39.
  86.  Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the 
management of chemotherapy-induced peripheral neuropathy: a phase 3 ran - 
domized, double-blind, placebo-controlled, crossover trial (N00C3). (cid:36)(cid:66)(cid:79)(cid:68)(cid:70)(cid:83). 
2007;110(9):2110-2118.
  87.  Pfizer, Inc. PhRMA web synopsis (Protocol A0081007): a randomized 
placebo-controlled trial of the efficacy and safety of pregabalin in the treatment 
of subjects with neuropathic pain associated with lumbo-sacral radiculopathy. 
2008.  http://pdf.clinicalstudyresults.org/documents/company-study_4268_0.pdf. 
Accessed January 12, 2010.
  88.  Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. 
Topiramate in chronic lumbar radicular pain.(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2005;6(12):829-836.
  89.  Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neu-
rostimulation  therapy  for  neuropathic  pain.  (cid:38)(cid:86)(cid:83)(cid:1) (cid:43)(cid:1) (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77).  2007;14(9):952- 
970.
  90.  Raskin  P,  Donofrio  PD,  Rosenthal  NR,  et  al.  Topiramate  vs  placebo 
in  painful  diabetic  neuropathy:  analgesic  and  metabolic  effects.  (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 
2004;63(5):865-873.
  91.  Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of 
depression and its implications for research on chronic neuropathic pain. (cid:47)(cid:70)(cid:86)(cid:14)
(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2005;65(12)(suppl 4):S7-S19.
  92.  Katz N. Methodological issues in clinical trials of opioids for chronic 
pain. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2005;65(12)(suppl 4):S32-S49.
  93.  Quessy SN, Rowbotham MC. Placebo response in neuropathic pain tri-
als. Pain. 2008;138(3):479-483.
  94.  Katz N. Enriched enrollment randomized withdrawal trial designs for 
analgesics. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2009;25(9):797-807.
  95.  Dworkin  RH, Turk  DC, Wyrwich  KW,  et  al.  Interpreting  the  clinical 
importance of treatment outcomes in chronic pain clinical trials: IMMPACT 
recommendations. (cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2008;9(2):105-121.

  96.  Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Inter-
preting  treatment  effects  in  randomised  trials.  (cid:35)(cid:46)(cid:43).  1998;316(7132):690- 
693.
  97.  Dworkin  RH, Turk  DC,  McDermott  MP,  et  al.  Interpreting  the  clini-
cal importance of group differences in chronic pain clinical trials: IMMPACT 
recommendations. Pain. 2009;146(3):238-244.
  98.  Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Ran-
domized double-blind study comparing the efficacy of gabapentin with amitrip-
tyline on diabetic neuropathy pain. (cid:34)(cid:83)(cid:68)(cid:73)(cid:1)(cid:42)(cid:79)(cid:85)(cid:70)(cid:83)(cid:79)(cid:1)(cid:46)(cid:70)d. 1999;159(16):1931-1937.
  99.  Chandra K, Shafiq N, Pandhi P, Malhotra S. Gabapentin versus nortrip-
tyline in post-herpetic neuralgia patients: a randomized, double-blind clinical 
trial—the GONIP trial.(cid:1)(cid:42)(cid:79)(cid:85)(cid:1)(cid:43)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:73)(cid:66)(cid:83)(cid:78)(cid:66)(cid:68)(cid:80)(cid:77)(cid:1)(cid:53)(cid:73)(cid:70)(cid:83). 2006;44(8):358-363.
  100.  Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Ef-
ficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison 
with pregabalin in patients with postherpetic neuralgia and diabetic polyneu-
ropathy: interim analysis from an open-label, two-stage adaptive, randomized, 
controlled trial. (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:37)(cid:83)(cid:86)(cid:72)(cid:1)(cid:42)(cid:79)(cid:87)(cid:70)(cid:84)(cid:85)(cid:74)(cid:72). 2009;29(4):231-241.
  101.  Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% 
Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and 
diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. 
(cid:36)(cid:86)(cid:83)(cid:83)(cid:1)(cid:46)(cid:70)(cid:69)(cid:1)(cid:51)(cid:70)(cid:84)(cid:1)(cid:48)(cid:81)(cid:74)(cid:79). 2009;25(7):1663-1676.
  102.  Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser 
PG. Comparison of the effectiveness of amitriptyline and gabapentin on chron-
ic neuropathic pain in persons with spinal cord injury.(cid:1)(cid:34)(cid:83)(cid:68)(cid:73)(cid:1)(cid:49)(cid:73)(cid:90)(cid:84)(cid:1)(cid:46)(cid:70)(cid:69)(cid:1)(cid:51)(cid:70)(cid:73)(cid:66)(cid:67)(cid:74)(cid:77)(cid:15)(cid:1)
2007;88(12):1547-1560.
  103.  Hansson PT, Attal N, Baron R, Cruccu G. Toward a definition of phar-
macoresistant neuropathic pain. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2009;13(5):439-440.
  104.  Jadad AR, Enkin MW. (cid:51)(cid:66)(cid:79)(cid:69)(cid:80)(cid:78)(cid:74)(cid:84)(cid:70)(cid:69)(cid:1)(cid:36)(cid:80)(cid:79)(cid:85)(cid:83)(cid:80)(cid:77)(cid:77)(cid:70)(cid:69)(cid:1)(cid:53)(cid:83)(cid:74)(cid:66)(cid:77)(cid:84)(cid:27)(cid:1)(cid:50)(cid:86)(cid:70)(cid:84)(cid:85)(cid:74)(cid:80)(cid:79)(cid:84)(cid:13)(cid:1)(cid:34)(cid:79)(cid:14)
(cid:84)(cid:88)(cid:70)(cid:83)(cid:84)(cid:1)(cid:66)(cid:79)(cid:69)(cid:1)(cid:46)(cid:86)(cid:84)(cid:74)(cid:79)(cid:72)(cid:84). 2nd ed. London, England: Blackwell/BMJ Books; 2007.
  105.  Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes 
zoster and postherpetic neuralgia in older adults. (cid:47)(cid:1)(cid:38)(cid:79)(cid:72)(cid:77)(cid:1)(cid:43)(cid:1)(cid:46)(cid:70)(cid:69). 2005;352(22): 
2271-2284.
  106.  Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors 
and prevention. (cid:45)(cid:66)(cid:79)(cid:68)(cid:70)(cid:85). 2006;367(9522):1618-1625.
  107.  Woolf  CJ.  Pain:  moving  from  symptom  control  toward  mechanism-
specific pharmacologic management. (cid:34)(cid:79)(cid:79)(cid:1)(cid:42)(cid:79)(cid:85)(cid:70)(cid:83)(cid:79)(cid:1)(cid:46)(cid:70)(cid:69). 2004;140(6):441-451.
  108.  Rowbotham MC. Mechanisms of neuropathic pain and their implications 
for the design of clinical trials. (cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90). 2005;65(12)(suppl 4):S66-S73.
  109.  Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. 
(cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2003;7(4):353-357.
  110.  Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the 
German Research Network on Neuropathic Pain (DFNS): standardized proto-
col and reference values. Pain. 2006;123(3):231-243.
  111.  Rolke R, Magerl W, Campbell KA, et al. Quantitative sensory testing: a 
comprehensive protocol for clinical trials. (cid:38)(cid:86)(cid:83)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 2006;10(1):77-88.
  112.  Scholz  J,  Mannion  RJ,  Hord  DE,  et  al. A  novel  tool  for  the  assess-
ment  of  pain:  validation  in  low  back  pain.  (cid:49)(cid:45)(cid:80)(cid:52)(cid:1) (cid:46)(cid:70)(cid:69).  2009;6(4):e1000047. 
doi:10.1371/journal.pmed.1000047.
  113.  Turk DC. Customizing treatment for chronic pain patients: who, what 
and why? (cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:43)(cid:1)(cid:49)(cid:66)(cid:74)(cid:79). 1990;6(4):255-270.

S14

(cid:46)(cid:66)(cid:90)(cid:80)(cid:1)(cid:36)(cid:77)(cid:74)(cid:79)(cid:1)(cid:49)(cid:83)(cid:80)(cid:68)(cid:15)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:46)(cid:66)(cid:83)(cid:68)(cid:73)(cid:1)(cid:19)(cid:17)(cid:18)(cid:17)(cid:28)(cid:25)(cid:22)(cid:9)(cid:20)(cid:10)(cid:9)(cid:84)(cid:86)(cid:81)(cid:81)(cid:77)(cid:10)(cid:27)(cid:52)(cid:20)(cid:14)(cid:52)(cid:18)(cid:21)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:69)(cid:80)(cid:74)(cid:27)(cid:18)(cid:17)(cid:15)(cid:21)(cid:17)(cid:23)(cid:22)(cid:16)(cid:78)(cid:68)(cid:81)(cid:15)(cid:19)(cid:17)(cid:17)(cid:26)(cid:15)(cid:17)(cid:23)(cid:21)(cid:26)(cid:1)(cid:1)(cid:1)(cid:1)(cid:114)(cid:1)(cid:1)(cid:1)(cid:1)(cid:88)(cid:88)(cid:88)(cid:15)(cid:78)(cid:66)(cid:90)(cid:80)(cid:68)(cid:77)(cid:74)(cid:79)(cid:74)(cid:68)(cid:81)(cid:83)(cid:80)(cid:68)(cid:70)(cid:70)(cid:69)(cid:74)(cid:79)(cid:72)(cid:84)(cid:15)(cid:68)(cid:80)(cid:78)

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings
.

a

